Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
GLP-1 Receptor Agonist (Oral)

Semaglutide (Oral)

Brand names: Rybelsus

Oral semaglutide is a GLP-1 receptor agonist taken as a daily tablet for type 2 diabetes (the first oral GLP-1 agonist), with weight and cardiovascular benefit.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

US labelling (FDA)

Reference — US labelling, may differ from UK

• RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis. • Take RYBELSUS or OZEMPIC tablets orally once daily on an empty stomach in the morning with water (up to 4 ounces of water); do not take with other liquids besides water. ( 2.1 ) • Swallow tablets whole. Do not split, crush, chew or dissolve in any solution. ( 2.1 ) • After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications. ( 2.1 ) • See the Full Prescribing Information for instructions on switching between RYBELSUS and OZEMPIC tablets ( 2.3 ) and from OZEMPIC injections to RYBELSUS or OZEMPIC tablets. ( 2.4 ) Recommended Starting, …

Source: US FDA prescribing information (openFDA / DailyMed), label dated 2026-01-30. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.

Clinical monograph

How it works

It is a GLP-1 analogue (glucose-dependent insulin secretion, reduced glucagon, slowed gastric emptying, reduced appetite), co-formulated with an absorption enhancer to allow oral absorption.

Prescribing in practice

  • Administration is strict — take it on an empty stomach with no more than a small sip of plain water, at least 30 minutes before any other food, drink or medicine, or it is poorly absorbed.
  • Gastrointestinal effects are common; pancreatitis is a rare but important risk; rapid glucose improvement may transiently worsen diabetic retinopathy.
  • It is contraindicated in medullary thyroid carcinoma/MEN 2 history and is not for type 1 diabetes or DKA.

Monitoring

Monitor glycaemia, weight and GI tolerance; arrange eye review where retinopathy is a concern.

Counselling the patient

  • Take it exactly as directed: empty stomach, a small sip of water only, then wait at least 30 minutes before anything else.
  • Report severe or persistent abdominal pain.

Evidence & guidelines

Improves glycaemia and weight with cardiovascular benefit (PIONEER programme; NICE NG28).

Reference: NICE NG28 (Type 2 DM); PIONEER Trials (NEJM 2019); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways